This initial data demonstrates that the shunt device can be safely implanted and early clinical improvement can be obtained in patients with heart failure and preserved or mildly reduced ejection fraction. Longer term follow-up is warranted.
Conclusions: Clopidogrel pretreatment is not associated with a reduction of mortality, MACE or ischemic endpoints in stable CAD scheduled for elective PCI, but with an excess of minor and any bleeding.
TCT-138
Clopidogrel Pretreatment in Non ST Elevation Acute Coronary Syndroms: no effect on mortality, decrease in ischemic endpoints at a price of more major bleeding.
Anne Bellemain-Appaix 1 , Stephen A. O'Connor 2 , Johanne Silvain 3 , Michel Cucherat 4 , Jean-Philippe Collet 5 , Francois Bernasconi 6 , Gilles Montalescot 7 1 CH La Fontonne Antibes, Antibes, France, 2 Pitié Salpétrière Hospital, Paris, France, 3 Pitie Salpetriere, Paris, France, 4 Chu Lyon, Lyon, MS, 5 Pitié Sapetriere, Paris, France, 6 CH La Fontonne Antibes, Antibes, MS, 7 Pitié-Salpêtrière University Hospital, Paris, France Background: Clopidogrel pretreatment is recommended for the treatment of NSTEACS patients (class I-B), at a time when the final revascularization strategy is not known. A previous meta-analysis focused on randomized trials suggested a tiny benefit in patients undergoing PCI. We performed a new meta-analysis of not only RCTs but also registries to assess the impact of clopidogrel pretreatment in NSTEACS patients. We evaluated the global effect independently of revascularization ("All" analysis) and in patients undergoing PCI ("PCI" analysis). Methods: We included studies on NSTEACS from MEDLINE, EMBASE, CCT and Biomedcentral. A random-effect model was applied. Pretreatment was defined as the administration of clopidogrel before PCI or catheterization. Primary efficacy and safety endpoints were all-cause mortality and major bleeding respectively, at longest follow up available. Secondary endpoints included Major Adverse Cardiac Events (MACE), Stroke, Stent Thrombosis, UVR. Results: Of the 393 titles identified, 6 articles (3 RCTs and 3 observational studies) met the inclusion criteria, published between August 2004 and January 2013, including 28 350 patients, in those 14 678 from RCTs. 52% underwent PCI. Among NSTEACS patients, clopidogrel pretreatment was not associated with a lower risk of mortality ("all": OR¼0,85, 95%CI(0,66-1,08), p¼0,18 or "PCI": OR¼0,81, 95% CI(0,58-1,13), p¼0,22). When considering all of studies (RCTs and registries) together, the reduction in Ischemic endpoints (OR¼0,81, 95%CI(0,7-0,94), p¼0,006) is counterbalanced by an increase in major bleeding (OR¼1,28, 95%CI(1,12-1,46), p¼0,0002). The reduction in ischemic endpoints is no more significant in the "PCI" analysis (OR¼0,82, 95%CI(0,65-1,03), p¼0,10) while there is still an excess of major bleeding in these patients (OR¼1,2, 95%CI(1-1,44), p¼0,048). ST, stroke and UVR were not different between groups (pretreatment vs. no) in both analyses. Conclusions: Clopidogrel pretreatment is not associated with a reduction of mortality in NSTEACS patients; the reduction of MACE is counterbalanced by major bleeding for "all" and "PCI" patients. The concept of systematic pretreatment in NSTE-ACS patients needs reappraisal in the contemporary era.
TCT-139
The effect of glycoprotein IIb/IIIa inhibitors on mortality and MACE following PCI for NSTEMI/UA James P. Howard 1 , Daniel A. Jones 1 , Krishnaraj Rathod 1 , Ajay Jain 1 , Charles Knight 1 , Anthony Mathur 1 , Andrew Wragg 1 1 Barts Health NHS Trust, London, United Kingdom Background: Meta-analyses of PCI in NSTEMI/UA have shown GPIIbIIIa inhibitors to be associated with a reduction in major adverse cardiac events at 30 days. However, many of the trials were carried out before the routine use P2Y12 inhibitors which act up-stream of GPIIbIIIa mediated platelet aggregation. Studies performed in the clopidogrel yield conflicting results and registry data indicates that these agents are less safe than trials would indicate. Methods: We undertook an observational study at an interventional cardiology center involving 5,227 patients undergoing PCI for NSTEMI/UA and receiving clopidogrel and aspirin. GPIIbIIIa use was at the discretion of the operator. Primary outcome was all cause mortality assessed at a median follow up of 4.6 years (IQR 3.0 -6.2 years). Results: 43.6% of patients were treated with GP IIb/IIIa inhibitors. The patients were younger, more likely to be male, and have fewer comorbidities including previous MI, CKD and PVD. They were less likely to suffer multivessel disease and more likely to have a successful angiographic result. Kaplan-Meier analysis showed GP IIbIIIa inhibitor use was associated with improved survival (p<0.001) and reduced MACE (p¼0.011), but increased bleeding (p¼0.001). On multivariate analysis the benefits were lost for both survival (HR 0.876; 95% CI 0.693 -1.108; p¼0.501) and MACE (HR 1.036; 95% CI 0.883 -1.216).
Parameter
Baseline Follow-up (d) Background: Prolonged dual anti-platelet therapy (DAPT) is recommended after an acute coronary syndrome (ACS) to reduce ischemic events, but is associated with increased rates of major and minor bleeding. The incidence of even lesser degrees of 'nuisance' bleeding on DAPT and its impact on quality of life (QOL) are largely unknown.
Methods: We studied 9290 ACS patients from the TRANSLATE ACS study who were treated with PCI and discharged alive between April 2010 to Sept 2012. Bleeding post-hospital discharge was defined via the BARC bleeding definitions. Our primary outcome was the 6 month EQ-5DÔ index score, based on the U.S. population preference weights. The EQ5D visual analog scale (VAS) at 6 months was a secondary outcome. To determine the association between nuisance bleeding and 6month QOL, we fit a mixed-effects linear regression model for 6 month EQ5D index adjusting for baseline EQ5D index, with site as random effect (hierarchical model) and other confounders of the relationship between bleeding and health status. We fit a similar model for EQ5D visual analog scale (VAS). Results: Of the 9,290 patients with ACS (mean age 61, 73% males, 89% Whites), 4134 (44.5%) underwent immediate PCI for STEMI, and 4308 (46.4%) underwent PCI for non-STEMI. A total of 849 (9.1%) patients experienced BARC I type nuisance bleeding. Those who experienced BARC I bleeding had lower scores on all 5 EQ5D domains (mobility, self-care, usual activities, pain and anxiety) and had a lower 5 point EQ5D VAS score. After adjustment for confounders, nuisance bleeding by 6 month was independently associated with a decrement in QOL at 6 month (-2.04 points on EQ5D VAS; 95% CI -0.93 to -3.15, P<0.001). Based on the EQ5D index score, the utility decrement associated with nuisance bleeding was 0.026, 95% CI 0.015 to 0.037, P-value <0.001. Conclusions: In TRANSLATE-ACS, we found that BARC Type I (nuisance) bleeding occurred in 1 of 10 patients after an ACS event and was associated with worse 6-month quality of life and utility. These findings suggest that even nuisance bleeds are relevant to patients and deserve greater attention in clinical recommendations for treatment and future clinical trials of prolonged DAPT therapies.
TCT-142
Prasugrel 5 mg inhibits platelet GPIIb-IIIa and P-Selectin expression in the very elderly -Results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients Background: Platelet surface P-selectin and activated GPIIb-IIIa are markers of platelet activation, degranulation and aggregation. In the TRITON trial prasugrel (Pras) 10 mg reduced ischemic events vs. clopidogrel (Clop) 75 mg but increased bleeding, notably in very elderly (VE) patients. Pras 5 mg is a treatment option in VE patients but data on its effect on GPIIb-IIIa and P-selectin expression is lacking. We performed a blinded, three-period cross-over study in stable CAD patients !75 y (VE) or 45-65 y (NE) examining expression of these biomarkers following Pras (5 or 10 mg) and Clop 75 mg. Methods: After a run-in on low dose aspirin, VE subjects (n¼23, 78 AE 5 y) and NE subjects (n¼22, 55 AE 5 y) were randomized to Pras (5 or 10 mg) or Clop 75 mg during three 12-day periods. ADP (20 mM)-stimulated platelet P-selectin and GPIIb-IIIa (PAC-1) were measured by flow-cytometry at baseline and at the end of each12-day dosing period. Results: PAC-1 and P-selectin (data not shown) expression after stimulation with 20 mM ADP did not differ between VE and NE at baseline or after any treatment period ( Figure) . PAC-1 expression was significantly reduced by pras 5 mg in both VE (p<0.01) and NE (p<0.05). In the VE the 5 mg dose had similar effect as pras 10 mg. Clop 75 mg did not significantly reduce PAC-1 in VE. P-selectin expression showed a similar profile (data not shown).
Conclusions:
As assessed by GPIIb-IIIa and P-selectin in stable CAD patients, Pras 5 mg significantly reduced ADP-induced platelet activation in the VE.
TCT-143
Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery Disease (OPERA) Study
